← Leaderboards
Peter Scott Pressman
University Of Colorado Denver
$2,985,823
Attributed
$4,991,805
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2020–24$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,991,805 · 3
By mechanism
R01$3,666,421 · 1
K23$979,840 · 1
R61$345,544 · 1
Top collaborators
- Huntington Potter3 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Huntington Potter$11,515,934
- Lawrence E Hunter$35,872,360
- James P Grigsby$7,318,061
- James O Stevens$3,186,594
- Jianfu Chen$12,824,478
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposCognitiveParticipantClinical TrialsS DiseaseS Disease PathologyPreparationNeuroimagingInvestigationMild Cognitive ImpairmentNeuropsychologyImageImpaired CognitionPrimary OutcomeAdultQuality Of LifeBaseNovel TherapeuticsLinguisticsLanguageDesignMemoryDementiaCommunities
Grant awards (9)
Computational Speech Analysis in Alzheimer's Disease and Other Neurocognitive Disorders$181,943
K23 · FY2024 · AG · contact PI
Computational Speech Analysis in Alzheimer's Disease and Other Neurocognitive Disorders$183,691
K23 · FY2023 · AG · contact PI
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease$2,326,177
R01 · FY2022 · AG
Computational Speech Analysis in Alzheimer's Disease and Other Neurocognitive Disorders$183,524
K23 · FY2022 · AG · contact PI
Computational Speech Analysis in Alzheimer's Disease and Other Neurocognitive Disorders (Supplement)$54,000
K23 · FY2022 · AG · contact PI
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease$1,340,244
R01 · FY2021 · AG
GM-CSF/sargramostim treatment to improve cognition in Down syndrome$345,544
R61 · FY2021 · AG
Computational Speech Analysis in Alzheimer's Disease and Other Neurocognitive Disorders$188,298
K23 · FY2021 · AG · contact PI
Computational Speech Analysis in Alzheimer's Disease and Other Neurocognitive Disorders$188,384
K23 · FY2020 · AG · contact PI